Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
A number of other analysts have also recently commented on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Monday. Wall Street Zen downgraded Humacyte from a "hold" rating to a "sell" rating in a research note on Sunday, August 17th. HC Wainwright lowered their target price on Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. TD Cowen lowered their target price on Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a report on Tuesday, August 12th. Finally, Barclays started coverage on shares of Humacyte in a research report on Wednesday, August 27th. They set an "overweight" rating and a $3.50 price objective for the company. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of "Moderate Buy" and an average target price of $9.29.
View Our Latest Stock Analysis on Humacyte
Humacyte Price Performance
Humacyte stock opened at $1.69 on Wednesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. Humacyte has a one year low of $1.15 and a one year high of $6.77. The stock's 50 day moving average is $1.75 and its 200 day moving average is $1.95. The firm has a market cap of $267.65 million, a P/E ratio of -3.76 and a beta of 1.89.
Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.94 million. As a group, research analysts expect that Humacyte will post -1.27 EPS for the current year.
Insider Buying and Selling
In related news, CEO Laura E. Niklason sold 591,685 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brady W. Dougan sold 591,685 shares of the firm's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Insiders sold 4,482,090 shares of company stock valued at $7,466,382 in the last three months. Insiders own 5.10% of the company's stock.
Institutional Investors Weigh In On Humacyte
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Endowment Wealth Management Inc. raised its holdings in shares of Humacyte by 5.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 109,458 shares of the company's stock worth $229,000 after acquiring an additional 5,350 shares during the last quarter. Wealth Effects LLC increased its holdings in Humacyte by 5.8% during the 2nd quarter. Wealth Effects LLC now owns 102,167 shares of the company's stock worth $214,000 after purchasing an additional 5,600 shares in the last quarter. ProShare Advisors LLC increased its holdings in Humacyte by 24.1% during the 2nd quarter. ProShare Advisors LLC now owns 31,493 shares of the company's stock worth $66,000 after purchasing an additional 6,106 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Humacyte by 14.4% during the first quarter. MetLife Investment Management LLC now owns 51,442 shares of the company's stock valued at $88,000 after buying an additional 6,482 shares during the last quarter. Finally, Concurrent Investment Advisors LLC boosted its position in shares of Humacyte by 17.5% during the second quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company's stock valued at $107,000 after buying an additional 7,615 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.
About Humacyte
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
